Insulin Aspart vs Insulin Glulisine
Insulin aspart and insulin glulisine are both ultra-rapid-acting insulin analogs designed to provide faster absorption and more physiological postprandial insulin profiles than regular human insulin. They achieve this through distinct amino acid modifications that alter zinc coordination and self-association behavior.
Molecular Modifications
Section titled “Molecular Modifications”Insulin Aspart
Section titled “Insulin Aspart”- Brand name: NovoRapid, Novolog
- Modification: ProB28 → Asp (aspartic acid)
- Mechanism: Proline at B28 normally promotes hexamer stability through hydrophobic interactions. Replacing it with the negatively charged aspartic acid destabilizes the hexamer-dimer equilibrium, accelerating dissociation to absorbable monomers.
- Zinc content: Standard (2 zinc ions per hexamer)
- Concentration: 100 units/mL (U-100)
Insulin Glulisine
Section titled “Insulin Glulisine”- Brand name: Apidra
- Modifications: AsnB3 → Lys, LysB29 → Glu
- Mechanism: The AsnB3Lys substitution reduces hexamer stability by disrupting the B-chain N-terminal conformation, while the LysB29Glu substitution introduces charge repulsion at the hexamer interface. The combined effect accelerates monomer dissociation.
- Zinc content: Reduced zinc (deliberately lowered to further destabilize hexamers)
- Concentration: 100 units/mL (U-100)
Comparison Table
Section titled “Comparison Table”| Property | Insulin Aspart | Insulin Glulisine |
|---|---|---|
| Brand name | NovoRapid, Novolog | Apidra |
| Modification | ProB28Asp | AsnB3Lys + LysB29Glu |
| Zinc content | Standard | Reduced |
| Hexamer stability | Reduced | Further reduced |
| Onset of action | 10–20 min | 10–20 min |
| Peak effect | 1–2 hrs | 1–2 hrs |
| Duration | 3–5 hrs | 3–5 hrs |
| Bioavailability | ~60–80% (SC) | ~60–80% (SC) |
Mechanism of Rapid Absorption
Section titled “Mechanism of Rapid Absorption”Insulin Aspart
Section titled “Insulin Aspart”The single ProB28Asp substitution has a focused effect on hexamer stability:
-
Reduced hydrophobic contacts: Proline’s cyclic structure normally contributes to hydrophobic packing at the hexamer interface. Aspartic acid’s negative charge disrupts these interactions.
-
Faster dissociation: The destabilized hexamer dissociates more rapidly into dimers and monomers after SC injection.
-
Standard zinc: The remaining zinc coordination maintains sufficient hexamer stability for formulation while allowing rapid dissociation.
-
Monomer absorption: Monomers cross capillary endothelium faster than hexamers, accelerating onset.
Insulin Glulisine
Section titled “Insulin Glulisine”The dual modification produces a more thorough destabilization:
-
Charge repulsion: The LysB29Glu substitution introduces negative charges at the hexamer interface, creating electrostatic repulsion between subunits.
-
Conformational disruption: The AsnB3Lys substitution alters the B-chain N-terminal conformation, further weakening hexamer contacts.
-
Reduced zinc: Deliberately lower zinc content means fewer zinc ions per hexamer, reducing coordination stability.
-
Maximum dissociation: The combined modifications produce the fastest dissociation among commercial insulin analogs.
Pharmacokinetic Comparison
Section titled “Pharmacokinetic Comparison”Absorption Phase
Section titled “Absorption Phase”| Parameter | Insulin Aspart | Insulin Glulisine |
|---|---|---|
| Onset | 10–20 min | 10–20 min |
| Time to peak | 60–90 min | 50–90 min |
| Tmax variability | Moderate | Moderate |
| Bioavailability | ~60–80% | ~60–80% |
| Absorption rate | Fast | Fastest |
Action Profile
Section titled “Action Profile”| Parameter | Insulin Aspart | Insulin Glulisine |
|---|---|---|
| Peak effect | 1–2 hrs | 1–2 hrs |
| Duration | 3–5 hrs | 3–5 hrs |
| Effective duration | 3–4 hrs | 3–4 hrs |
| Late insulinemia | Mild | Minimal |
Both analogs produce more physiological postprandial insulin profiles than regular human insulin, with faster onset and shorter duration that better match carbohydrate absorption kinetics.
Comparison with Regular Insulin
Section titled “Comparison with Regular Insulin”| Parameter | Regular Insulin | Aspart | Glulisine |
|---|---|---|---|
| Onset | 30–60 min | 10–20 min | 10–20 min |
| Peak | 2–4 hrs | 1–2 hrs | 1–2 hrs |
| Duration | 6–8 hrs | 3–5 hrs | 3–5 hrs |
| Pre-meal timing | 30–45 min before | 0–15 min before | 0–15 min before |
| Flexibility | Low | High | High |
Clinical Efficacy
Section titled “Clinical Efficacy”Glycemic Control
Section titled “Glycemic Control”| Parameter | Aspart | Glulisine |
|---|---|---|
| HbA1c reduction | ~0.5–1.0% | ~0.5–1.0% |
| Postprandial glucose control | Superior to regular | Superior to regular |
| Fasting glucose | Comparable | Comparable |
| Time in range (CGM) | Improved vs regular | Improved vs regular |
Hypoglycemia
Section titled “Hypoglycemia”| Parameter | Aspart | Glulisine |
|---|---|---|
| Overall hypoglycemia | Comparable to regular | Comparable to regular |
| Nocturnal hypoglycemia | Slightly lower | Slightly lower |
| Late postprandial hypo | Lower (shorter duration) | Lower (shorter duration) |
The shorter duration of action reduces the risk of late postprandial hypoglycemia, particularly when dosed immediately before or with meals.
Dosing and Administration
Section titled “Dosing and Administration”| Parameter | Insulin Aspart | Insulin Glulisine |
|---|---|---|
| Typical dose | Based on carb ratio/Correction | Based on carb ratio/Correction |
| Timing | 0–15 min before meals | 0–15 min before meals |
| Flexibility | Can dose after meals | Can dose after meals |
| IV use | Yes (short-term) | Investigational |
| Pump use | Yes (approved) | Yes (approved) |
| Mix with NPH | Can be mixed | Cannot be mixed (package insert) |
Formulation Differences
Section titled “Formulation Differences”| Parameter | Insulin Aspart | Insulin Glulisine |
|---|---|---|
| Preservative | Metacresol | Metacresol |
| Zinc content | ~50 mcg/mL | Reduced (~15 mcg/mL) |
| m-Cresol | Yes | Yes |
| Phenol | Yes | Yes |
| pH | ~7.4 | ~7.4 |
| Vehicle | Isotonic aqueous | Isotonic aqueous |
The reduced zinc in glulisine is a deliberate formulation strategy to further destabilize hexamers, not merely a consequence of the amino acid modifications.
Ultra-Rapid Formulations
Section titled “Ultra-Rapid Formulations”Both aspart and glulisine have ultra-rapid formulations that further accelerate absorption:
| Formulation | Aspart | Glulisine |
|---|---|---|
| Standard | NovoRapid | Apidra |
| Ultra-rapid | Fiasp (with niacinamide) | Under development |
| Mechanism | Niacinamide vasodilation | Additional destabilization |
| Onset | 5–15 min | 5–15 min |
| Fiasp advantage | Faster early absorption | — |
Fiasp (faster-acting insulin aspart) adds niacinamide (vitamin B3) to the formulation, which promotes local vasodilation and accelerates initial absorption. This reduces the onset to approximately 5–15 minutes.
When to Choose Each
Section titled “When to Choose Each”| Clinical Scenario | Preferred Agent |
|---|---|
| Standard prandial insulin | Either (equivalent efficacy) |
| Insulin pump therapy | Aspart (more pump data) |
| Very rapid onset needed | Glulisine (marginally faster) |
| Mixing with NPH | Aspart (compatible) |
| Post-meal dosing flexibility | Either |
| Cost sensitivity | Aspart (more generic competition) |
Key Takeaways
Section titled “Key Takeaways”Insulin aspart and insulin glulisine achieve ultra-rapid action through distinct molecular strategies. Aspart’s single ProB28Asp substitution reduces hexamer stability through disrupted hydrophobic contacts, while glulisine’s dual AsnB3Lys/LysB29Glu substitutions plus reduced zinc content produce the fastest dissociation among commercial analogs. Both achieve comparable clinical efficacy, with the primary differences being formulation compatibility (aspart mixes with NPH, glulisine does not) and the availability of ultra-rapid formulations (Fiasp for aspart). The choice between them is largely a matter of clinical context and formulary availability.